{
  "guideline": {
    "id": "PA166222801",
    "name": "Annotation of DPWG Guideline for flucytosine and DPYD",
    "source": "DPWG",
    "version": 8,
    "url": "https://www.pharmgkb.org/guidelineAnnotation/PA166222801",
    "relatedChemicals": [
      {
        "id": "PA449654",
        "name": "flucytosine",
        "symbol": null
      }
    ],
    "relatedGenes": [
      {
        "id": "PA145",
        "name": "dihydropyrimidine dehydrogenase",
        "symbol": "DPYD"
      }
    ],
    "recommendation": true,
    "guidelineGenes": [
      {
        "alleles": [
          {
            "id": 1451446701,
            "_label": "Reference",
            "function": {
              "term": "Normal function",
              "termId": "haplotypeTags:1445558335"
            }
          },
          {
            "id": 1451446704,
            "_label": "c.1129-5923C>G, c.1236G>A (HapB3)",
            "function": {
              "term": "Decreased function",
              "termId": "haplotypeTags:1445558331"
            }
          },
          {
            "id": 1451446702,
            "_label": "c.1679T>G (*13)",
            "function": {
              "term": "No function",
              "termId": "haplotypeTags:1445558515"
            }
          },
          {
            "id": 1451818381,
            "_label": "c.1905+1G>A (*2A)",
            "function": {
              "term": "No function",
              "termId": "haplotypeTags:1445558515"
            }
          },
          {
            "id": 1451446703,
            "_label": "c.2846A>T",
            "function": {
              "term": "Decreased function",
              "termId": "haplotypeTags:1445558331"
            }
          }
        ],
        "gene": {
          "chr": {
            "id": "PA503",
            "name": "chr1",
            "symbol": null
          },
          "strand": "minus",
          "id": "PA145",
          "name": "dihydropyrimidine dehydrogenase",
          "symbol": "DPYD"
        }
      }
    ]
  },
  "annotationGroups": [
    {
      "id": "PA166244203",
      "name": "Activity Score 2",
      "strength": {
        "term": "N/A",
        "termId": "guidelineStrength:981501929"
      },
      "rxChangeStatus": {
        "term": "No",
        "termId": "rxChange:1448602495"
      },
      "genePhenotypes": [
        "DPYD:Normal function/Normal function"
      ],
      "metabolizerStatus": null,
      "recommendation": {
        "id": 1451446767,
        "html": "<p>The guideline does not provide a recommendation for flucytosine in patients with a DPYD activity score of 2.</p>\n"
      },
      "implications": {
        "id": 1451446765,
        "html": "<p>The guideline does not provide a description of the impact of a DPYD activity score of 2 on flucytosine.</p>\n"
      },
      "activityScore": {
        "id": 1451446764,
        "html": "<p>2</p>\n"
      }
    },
    {
      "id": "PA166244202",
      "name": "Activity Score 1.5",
      "strength": {
        "term": "N/A",
        "termId": "guidelineStrength:981501929"
      },
      "rxChangeStatus": {
        "term": "Possibly",
        "termId": "rxChange:1448602496"
      },
      "genePhenotypes": [
        "DPYD:Decreased function/Normal function"
      ],
      "metabolizerStatus": null,
      "recommendation": {
        "id": 1451447163,
        "html": "<ul>\n<li>Be alert to the occurrence of severe side effects, such as leukopaenia, neutropaenia, thrombocytopaenia and diarrhoea\n<ul>\n<li>In the majority of cases, side effects of flucytosine occur in the first two to three weeks of the treatment. Flucytosine should be stopped if severe side effects occur.</li>\n</ul>\n</li>\n</ul>\n"
      },
      "implications": {
        "id": 1451447161,
        "html": "<p>A very low risk of severe toxicity is increased by gene variation. A small proportion of flucytosine is converted to fluorouracil. Patients with this gene variation are more likely to have a reaction to fluorouracil, but generally tolerate low doses (50-75% of the standard fluorouracil dose).</p>\n"
      },
      "activityScore": {
        "id": 1451447160,
        "html": "<p>1.5</p>\n"
      }
    },
    {
      "id": "PA166244182",
      "name": "Activity Score PHENO",
      "strength": {
        "term": "N/A",
        "termId": "guidelineStrength:981501929"
      },
      "rxChangeStatus": {
        "term": "Possibly",
        "termId": "rxChange:1448602496"
      },
      "genePhenotypes": [
        "DPYD:Decreased function/Decreased function",
        "DPYD:Decreased function/No function"
      ],
      "metabolizerStatus": null,
      "recommendation": {
        "id": 1451447171,
        "html": "<ul>\n<li>Be alert to the occurrence of severe side effects, such as leukopaenia, neutropaenia, thrombocytopaenia and diarrhoea.\n<ul>\n<li>In the majority of cases, side effects of flucytosine occur in the first two to three weeks of the treatment. Flucytosine should be stopped if severe side effects occur.</li>\n</ul>\n</li>\n</ul>\n"
      },
      "implications": {
        "id": 1451447169,
        "html": "<p>A very low risk of severe toxicity is increased by gene variation. A small proportion of flucytosine is converted to fluorouracil. Patients with this gene variation are more likely to have a reaction to fluorouracil, but generally tolerate low doses (15-50% of the standard fluorouracil dose).</p>\n"
      },
      "activityScore": {
        "id": 1451447168,
        "html": "<p>DPD enzyme activity cannot be predicted correctly, an additional phenotyping test is required to determine the DPD enzyme activity.</p>\n"
      }
    },
    {
      "id": "PA166244201",
      "name": "Activity Score 1",
      "strength": {
        "term": "N/A",
        "termId": "guidelineStrength:981501929"
      },
      "rxChangeStatus": {
        "term": "Yes",
        "termId": "rxChange:1448602497"
      },
      "genePhenotypes": [
        "DPYD:No function/Normal function"
      ],
      "metabolizerStatus": null,
      "recommendation": {
        "id": 1451447175,
        "html": "<ul>\n<li>Be alert to the occurrence of severe side effects, such as leukopaenia, neutropaenia, thrombocytopaenia and diarrhoea\n<ul>\n<li>In the majority of cases, side effects of flucytosine occur in the first two to three weeks of the treatment. Flucytosine should be stopped if severe side effects occur</li>\n</ul>\n</li>\n</ul>\n"
      },
      "implications": {
        "id": 1451447173,
        "html": "<p>A very low risk of severe toxicity is increased by gene variation. A small proportion of flucytosine is converted to fluorouracil. Patients with this gene variation are more likely to react to fluorouracil, but generally tolerate low doses (approximately 50% of the standard fluorouracil dose).</p>\n"
      },
      "activityScore": {
        "id": 1451447172,
        "html": "<p>1</p>\n"
      }
    },
    {
      "id": "PA166244181",
      "name": "Activity Score 0",
      "strength": {
        "term": "N/A",
        "termId": "guidelineStrength:981501929"
      },
      "rxChangeStatus": {
        "term": "No",
        "termId": "rxChange:1448602495"
      },
      "genePhenotypes": [
        "DPYD:No function/No function"
      ],
      "metabolizerStatus": null,
      "recommendation": {
        "id": 1451838436,
        "html": "<p>Avoid flucytosine</p>\n"
      },
      "implications": {
        "id": 1451838434,
        "html": "<p>A risk of life-threatening toxicity is increased by gene variation. A small proportion of flucytosine is converted to fluorouracil and patients with this gene variation are intolerant even to small quantities of fluorouracil.</p>\n"
      },
      "activityScore": {
        "id": 1451838433,
        "html": "<p>0</p>\n"
      }
    }
  ],
  "citations": [],
  "version": "2022-11-05-00-25"
}